Thermo Fisher Scientific Inc. $TMO Shares Sold by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 86.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,952 shares of the medical research company’s stock after selling 289,518 shares during the period. Thermo Fisher Scientific accounts for 1.3% of Lombard Odier Asset Management Europe Ltd’s holdings, making the stock its 13th biggest position. Lombard Odier Asset Management Europe Ltd’s holdings in Thermo Fisher Scientific were worth $26,627,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of TMO. Assetmark Inc. lifted its holdings in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares during the last quarter. Mackenzie Financial Corp raised its position in Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after purchasing an additional 62,790 shares during the period. NEOS Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific by 28.6% in the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after purchasing an additional 11,415 shares during the last quarter. Factory Mutual Insurance Co. increased its position in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock worth $47,985,000 after purchasing an additional 2,500 shares during the last quarter. Finally, North Dakota State Investment Board acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at about $7,505,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TMO shares. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Barclays decreased their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Piper Sandler initiated coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $608.95.

Thermo Fisher Scientific Trading Down 0.2%

NYSE:TMO opened at $472.73 on Wednesday. The company has a market capitalization of $175.68 billion, a PE ratio of 25.99, a P/E/G ratio of 2.10 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The stock’s 50 day moving average price is $478.34 and its 200 day moving average price is $525.54.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the previous year, the company earned $5.15 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.